MALARONE PAEDIATRIC Film-coated tablet Ref.[51433] Active ingredients: Atovaquone Proguanil Proguanil and Atovaquone

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2023  Publisher: Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

Product name and form

Malarone paediatric 62.5mg/25 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet.

Round biconvex, pink tablets engraved ‘GX CG7’ on one side.

Qualitative and quantitative composition

Each Malarone paediatric tablet contains 62.5 mg atovaquone and 25 mg proguanil hydrochloride.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Atovaquone

Atovaquone is a selective and potent inhibitor of the eukaryotic mitochondrial electron transport chain in a number of parasitic protozoa and the parasitic fungus P. jiroveci. The site of action appears to be the cytochrome bc1 complex (complex III).

Proguanil

Proguanil is an antimalarial drug and dihydrofolate reductase inhibitor. It acts like the other antifolate antimalarials by interfering with the folic-folinic acid systems and thus exerts its effect mainly at the time the nucleus is dividing. Proguanil is effective against the exoerythrocytic forms of some strains of plasmodium falciparum but it has little or no activity against the exoerythrocytic forms of p. Vivax.

Proguanil and Atovaquone

Atovaquone and proguanil interfere with two different pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication. The mechanism of action of atovaquone against P. falciparum is via inhibition of mitochondrial electron transport, and collapse of mitochondrial membrane potential. One mechanism of action of proguanil, via its metabolite cycloguanil, is inhibition of dihydrofolate reductase, which disrupts deoxythymidylate synthesis. Proguanil also has antimalarial and is able to potentiate the ability of atovaquone to collapse mitochondrial membrane potential in malaria parasites. This latter mechanism may explain the synergy seen when atovaquone and proguanil are used in combination.

List of Excipients

Core:

Poloxamer 188
Microcrystalline cellulose
Low-substituted hydroxypropyl cellulose
Povidone K30
Sodium starch glycollate (Type A)
Magnesium stearate

Coating:

Hypromellose
Titanium dioxide E171
Iron oxide red E172
Macrogol 400
Polyethylene glycol 8000

Pack sizes and marketing

PVC-aluminium/paper child-resistant foil blister pack containing 12 tablets.

Marketing authorization holder

Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

Marketing authorization dates and numbers

PL 10949/0363

Date of first authorisation: 15 July 2002
Date of latest renewal: 13 July 2012

Drugs

Drug Countries
MALARONE Austria, Australia, Canada, Estonia, Spain, Finland, France, Ireland, Israel, Japan, Lithuania, Malta, Netherlands, New Zealand, Poland, Singapore, United Kingdom, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.